Franzius C, Schulte M, Hillmann A, Winkelmann W, Jürgens H, Bockisch A, Schober O
Klinik und Poliklinik für Nuklearmedizin, Westfälische Wilhelms-Universität Münster.
Chirurg. 2001 Sep;72(9):1071-7. doi: 10.1007/s001040170078.
In the framework of the 3rd Consensus Conference "PET in Oncology" the bone and soft-tissue tumors study group evaluated the present position of PET for these tumor entities on the basis of international publications.
After a systematic review of the literature, publications were evaluated according to previously defined quality criteria. For various indications the clinical usefulness of PET was assessed using a classification system.
Most studies had been performed with a small number of patients (n < 35). Therefore, only 8 of 46 publications were judged relevant. On the basis of these literature data, use of FDG-PET for grading was classified 1b (literature results predominantly show clinical usefulness). As before (1995/97), all other indications were categorized with 3 (assessment not yet possible, literature data inadequate).
According to the opinion of experts, the detection of osseous metastases of Ewing's sarcoma, therapy monitoring and the diagnosis of recurrences are potentially useful clinical indications for FDG-PET. Therefore, prospective studies with large patient groups are essential to further evaluate the benefit of FDG-PET in these indications.
在第三届“肿瘤学中的PET”共识会议框架内,骨与软组织肿瘤研究小组根据国际出版物评估了PET在这些肿瘤实体中的当前地位。
在对文献进行系统回顾后,根据先前定义的质量标准对出版物进行评估。对于各种适应症,使用分类系统评估PET的临床实用性。
大多数研究的患者数量较少(n < 35)。因此,46篇出版物中只有8篇被认为相关。根据这些文献数据,FDG-PET用于分级被归类为1b(文献结果主要显示临床实用性)。与之前(1995/97年)一样,所有其他适应症均归类为3级(评估尚不可能,文献数据不足)。
根据专家意见,检测尤因肉瘤的骨转移、治疗监测和复发诊断是FDG-PET潜在有用的临床适应症。因此,开展有大量患者群体的前瞻性研究对于进一步评估FDG-PET在这些适应症中的益处至关重要。